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Mutations in transcription factor (TF) genes are
frequently observed in tumors, often leading to aber-
rant transcriptional activity. Unfortunately, TFs are
often considered undruggable due to the absence
of targetable enzymatic activity. To address this
problem, we developed CRAFTT, a computational
drug-repositioning approach for targeting TF activ-
ity. CRAFTT combines ChIP-seq with drug-induced
expression profiling to identify small molecules that
can specifically perturb TF activity. Application to
ENCODE ChIP-seq datasets revealed known drug-
TF interactions, and a global drug-protein network
analysis supported these predictions. Application
of CRAFTT to ERG, a pro-invasive, frequently over-
expressed oncogenic TF, predicted that dexametha-
sone would inhibit ERG activity. Dexamethasone
significantly decreased cell invasion and migration
in an ERG-dependent manner. Furthermore, analysis
of electronic medical record data indicates a protec-
tive role for dexamethasone against prostate cancer.
Altogether, our method provides a broadly appli-
cable strategy for identifying drugs that specifically
modulate TF activity.INTRODUCTION
Transcription factors (TFs) are frequently mutated in cancer.
These include factors that function in a variety of ways, including
nuclear hormone receptors, resident nuclear proteins, and latent
cytoplasmic factors (Darnell, 2002). One classic example of a
recurrently altered TF is the tumor suppressor TF gene p53,
which is mutated in up to 40% of human tumors (Libermann
and Zerbini, 2006) yet has remained a highly elusive target for re-
activation (Mees et al., 2009). Other examples include c-Myc,2348 Cell Reports 15, 2348–2356, June 14, 2016 ª 2016 The Author(
This is an open access article under the CC BY-NC-ND license (http://which is also among themost commonly altered genes in cancer
(Ablain et al., 2011), ERG, and other ETS-family factors, which
are fused to the androgen-controlled promoters in more than
50% of prostate cancer patients (Rickman et al., 2012).
Inhibition of oncogenes and reactivation of tumor suppres-
sors have become well-established goals in anticancer drug
development (Darnell, 2002). Yet TFs are generally considered
difficult to drug (Mees et al., 2009). If a strategy could be devel-
oped for safely and effectively modulating the activity of specific
TFs, it would affect the treatment of tumor types and subtypes
driven by oncogenic TFs. In theory, a similar strategy could be
applied to reactivate the lost activity of tumor-suppressive fac-
tors. Potential mechanisms for pharmacological activation or in-
hibition include disruption of direct DNA binding, perturbation or
prevention of the interaction with cofactors and other interacting
proteins (Libermann and Zerbini, 2006), and disruption or acti-
vation of upstream signaling mechanisms (Mees et al., 2009).
Disrupting interactions with cofactors and other regulatory pro-
teins is broadly viewed as one of the most promising ap-
proaches to altering the activity and function of TFs implicated
in disease.
One of the first and best-understood successes in disrupting
TFs was the identification of the combination of retinoic acid
and arsenic trioxide for inhibition of the PML/RARA fusion onco-
gene in acute promyelocytic leukemia (APL). The PML/RARA
fusion results in the repression of many genes, which in turn
blocks the differentiation phenotype that is characteristic of
APL (Ablain et al., 2011). The retinoic acid-arsenic combination
induces PML/RARA degradation, which reactivates the silenced
genes (Ablain et al., 2011). A small molecule, JQ1, has been
discovered to inhibit c-Myc and n-Myc, both key regulators of
cell proliferation, by inhibiting BET bromodomain proteins, which
function as regulatory factors for c-Myc and n-Myc (Delmore
et al., 2011; Puissant et al., 2013). While important, these studies
are based on extremely detailed knowledge of the mechanisms
and structures of the cofactors required for TF activity. Such
knowledge is not always available, and as a result, there is no
systematic way to identify small molecules that can specifically
disrupt TF activity.s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Methodology Overview
(A) Alterations in TFs are frequently observed in
tumors, leading to aberrant activity. Our method
integrates transcriptional binding data and drug-
induced gene expression profiles to make pre-
dictions about drugs thatmay affect transcriptional
activity. This disruption can occur through a variety
of mechanisms, including the inhibition or re-
activation of direct binding to DNA or disruption via
cofactors.
(B) Application of our method to JQ1 expression
profiles and MYC ChIP-seq. The left panel illus-
trates the results for the GSEA involving JQ1 and
MYC. The lowest plot in the left panel shows the
log2 differential expression profile for JQ1, with the
locations of the MYC target genes marked directly
above. Directly above that are the running enrich-
ment score and a histogram of the MYC target
gene frequency across the drug-induced ranked
list, which illustrate whether the MYC target gene
set is enriched in the under- or overexpression
regions. In the middle panel, the shortest path
between JQ1 and MYC is shown, with BET Bro-
modomain proteins lying between the two. On the
right, we illustrate that the application of JQ1 re-
sults in the downregulation of MYC target genes.
See also Figure S1.To address this unmet need, we developed CRAFTT, a
computational drug-repositioning approach for targeting TFs.
Altogether, our method provides a broadly applicable strategy
to identify drugs and small molecules that specifically target
the activity of individual TFs. Because a significant number of tu-
mors are driven by oncogenic TFs or have lost tumor-suppres-
sive TFs, our approach could potentially affect the development
of new therapeutic strategies. For example, our method may be
applicable to other therapeutically elusive factors with onco-
genic activity, such as FOXA1, or for reactivating the expression
program of tumor-suppressive TFs such as p53.
RESULTS
Computational Drug-Repositioning Approach
Rediscovers JQ1 for MYC Inhibition
We first set out to quantify the prevalence of somatic mutations
in TF genes.We found that 45.1% (p < 0.001, permutation test) of
cancer samples in the Catalogue of SomaticMutations in Cancer
(COSMIC) reported a mutation in a TF (Figure S1). Furthermore,Cell RTFs constitute a significant proportion
(18.1%) of the genes in the Sanger Insti-
tute’s Cancer Gene Census. This
confirmed that the prevalence of genomic
alterations in TF genes in cancer is sub-
stantial and further indicates that TFs
should constitute a major class of anti-
cancer drug targets.
To address this need, we reasoned that
if drugs could be identified that specif-
ically disrupt the expression of the directtarget genes of a given TF, then these drugs would represent
good candidates for perturbing the driving role of that particular
TF in cancer (Figure 1A). We propose CRAFTT, which consists of
two major steps: (1) prediction and (2) prioritization using
network analysis.
For the prediction step, we compute a score that represents
how the direct targets of a TF are modulated by a particular
drug. Direct transcriptional target genes are identified using
chromatin immunoprecipitation sequencing (ChIP-seq) binding
data. The drug treatment-induced modulation profiles are ob-
tained by analyzing expression profiles from drug perturbation
experiments, such as those in the Broad Institute’s Connectivity
Map (CMap) (Figure 1A) (Lamb et al., 2006), and generating
ranked gene lists by sorting the genes frommost downregulated
to most upregulated upon treatment. For a given TF and drug
pair, we implement the Broad Institute’s gene set enrichment
analysis (GSEA) (Subramanian et al., 2005) approach, using the
drug-induced ranked gene list and the TF’s direct target gene
set (see Experimental Procedures). Each GSEA yields a normal-
ized enrichment score (NES) and a corresponding p valueeports 15, 2348–2356, June 14, 2016 2349
indicating whether the TF target gene set is mobilized as a whole
by the drug, either toward downregulation (NES > 0) or toward
upregulation (NES < 0). The p values are corrected for multiple
testing using family-wise error rate (FWER) controlling proce-
dures. This multiple testing procedure is applied to each drug
perturbation profile individually, correcting across all TF gene
sets that we are testing. We consider a drug to be predicted to
affect TF activity if the FWER-adjusted p value for the pair was
less than 10% (FWER < 0.1).
Next, we use network analysis to prioritize the predictions
made in the first step of CRAFTT. We reasoned that if many of
our predictions are true drug-TF modulatory interactions, the
network path between a drug and its predicted target TF should
be relatively short. This is due to the presumed mechanisms un-
derlying the interaction, which would involve signalingmolecules
immediately upstream of TFs in signaling pathways and tran-
scriptional cofactors. More broadly, we expected that the drug
and target TFs would be functionally related and therefore be
located near each other in a global drug-protein network. We
curated a biological network that contains 22,399 protein-coding
genes, 6,679 drugs, and 170 TFs. The protein-protein interac-
tions represent established interactions (Aksoy et al., 2013;
Das and Yu, 2012; Khurana et al., 2013), which include both
physical (protein-protein) and non-physical (phosphorylation,
metabolic, signaling, and regulatory) interactions. The drug-pro-
tein interactions were curated from several drug target data-
bases (Aksoy et al., 2013; Knox et al., 2011).
For each drug-TF pair, we calculated the network path length
(shortest path) between the TF and the drug. To account for the
biases associated with TFs or drugs with large numbers of tar-
gets, we calculated a normalized path length, which we defined
to be the probability that the path length would be observed
given randomized networks that conserved TF and drug degrees
(Gobbi et al., 2014). We then generate a final prediction score,
which we term the modulation index (MI). The MI is a weighted
score that scales the NES for the drug-TF pair (NESd,TF) by the
normalized network path length (NPLd,TF) (see Experimental Pro-
cedures). The proposed approach does not make any assump-
tions about the mechanisms by which a drug can disrupt the
expression program of TFs (Figure 1A). Such disruption can
occur in a variety of ways, e.g., disruption of interaction with co-
factors and DNA binding disruption.
As a first proof of principle, we applied this approach to JQ1-
induced gene expression profiles derived from another study
(Puissant et al., 2013), all CMap drug-induced expression pro-
files (Lamb et al., 2006), and MYC direct target genes, which
were derived from Encyclopedia of DNA Elements (ENCODE)
ChIP-seq data (ENCODE Project Consortium, 2011). We found
that JQ1 significantly downregulated a substantial fraction
(47%) of the 1,250 MYC direct target genes identified by ChIP-
seq (FWER < 0.001). Furthermore, we found that JQ1 had the
lowest FWER-adjusted p value, highest enrichment score
(NES = 5.12), and shortest possible network path length of 2,
given the underlying mechanisms of the true interaction. This
indicated that JQ1 is the best candidate (MIJQ1,MYC = 5,120) of
the 1,310 drugs that we investigated. Thus, as predicted, our
method correctly identified the inhibitory effect of JQ1 on
MYC-induced transcription (Figure 1B).2350 Cell Reports 15, 2348–2356, June 14, 2016Systematic Drug-TF Analysis Predicts that Candidate
Small Molecules Can Disrupt TFs
Next, we applied our drug repositioning approach to 166 ChIP-
seq experiments from ENCODE (ENCODE Project Consortium,
2011) and to the 1,309 drug perturbation experiments in CMap
(Figure S2) (Lamb et al., 2006). This approach identified 37,638
candidate drug-TF pairs (out of 218,603 possible combinations)
(Figure 2A). These candidates included 21,495 predicted acti-
vating interactions (a drug induces activation of many direct TF
targets) and 16,143 inhibiting interactions (a drug induces
repression of many direct TF targets). In particular, there were
1,673 selective predictions involving 49 TFs and 1,308 drugs
that we have greater confidence in due to the selectivity of the
prediction (see Supplemental Experimental Procedures for
more details). Top specific predictions for both drug-induced
inhibition and drug-induced activation of each TF are shown in
Table S1.
Several predicted drug-TF interactions are consistent with the
known activity of the drugs involved. For example, all four known
heat shock protein 90 (HSP90) inhibitors that were included both
in our biological network and in CMap were predicted to repress
HSF1 activity, which was expected given HSP90’s chaperone
effect on HSF1(Conde et al., 2009). These four HSP90 inhibitors
were monorden (FWER = 0.054), 17-AAG (FWER = 0.031), 17-
DMAG (FWER = 0.085), and geldanamycin (FWER < 0.001). In
addition, novobiocin, whose antagonism of HSP90 is reported
in literature but was not annotated in our network, was recovered
by CRAFTT for disruption of HSF1 (FWER = 0.031). Novobiocin
and geldanamycin had been previously identified to disrupt
HSF1 activity through inhibition of HSP90 chaperone activity,
operating through the inhibition of HSP90 autophosphorylation
for novobiocin and the binding to the HSP90 site in geldanamy-
cin (Conde et al., 2009). We found experimental evidence for
numerous other predicted drug-TF interactions for both inhibi-
tion and reactivation, which can be found in Table S2.
Because experimental validations are not available for most
drug-TF pairs, we turned to network analysis to further evaluate
the prediction step of our approach.Within our curated biological
network, therewere35knowndrug-TF interactions thatwerealso
present in both the ENCODE and the CMap datasets. Most of
these combinations involved a glucocorticoid receptor (GR)
agonist (26 combinations) or a HDAC inhibitor (7 combinations).
Of the 35 known drug-TF combinations, CRAFTT was able to
correctly predict more than expected (n = 21, p = 1.708e-8, bino-
mial test). In particular, CRAFTT predicted well both the GR ago-
nists (p = 6.524e-8, binomial test) and the HDAC inhibitors
(p = 0.01978, binomial test). Furthermore, we observed that the
drugperturbationprofileswithin theseclasseswerequitedistinct;
thus, this is not likely due to recovery of the same signal. In addi-
tion, about 85%of these combinationswere nominally significant
(p = 3.42e-8), which indicates that our approachwas able to iden-
tify evidence of the targeting event. The drug-TF pairs that were
not rediscovered generally involved drugs or TFs that targeted
many genes or were predicted to interact with most other drugs
or TFs (non-specific). In general, we found that CRAFTT had
limited predictive ability for drugs with more than 25 targets and
TFswithmore than 2,300 target genes (see Supplemental Exper-
imental Procedures for more details).
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Figure 2. Systematic Analysis of 166 TFs
and 1,309 Drug Perturbation Experiments
Identifies Approximately 38,000 Candidate
TF-Drug Pairs
(A) Heatmap of the FWER p values for all TF-drug
pairs involving 166 ChIP-seq experiments from
ENCODE and the 1,309 drugs from CMap. In the
middle panels, we highlight a subset of non-pre-
dictions with high GSEA FWER scores (top) and
predictions with low GSEA FWER scores (bottom).
On the right, we illustrate that we would expect the
candidate TF-drug pairs to have shorter network
path lengths than those of non-predictions. For
example, the non-predicted pair ETS1-betazole
(p = 1, GSEA nominal p value) has a path length
of 4, while the predicted pair FOXA2-pro-
chlorperazine (p < 0.001, GSEA nominal p value)
has a path length of 2.
(B) Normalized network path lengths for the spe-
cific predictions (FWER < 0.1) and non-predictions
(FWER = 1). Statistical significance was evaluated
using the Mann-Whitney test.
(C) Network visualization of HSF1, three HSP90
inhibitors covered in CMap and our network
(monorden, 17-AAG, and 17-DMAG), and four
other drugs not predicted to disrupt HSF1
disruption (clomifene, yohimbine, oxprenolol, and
cortisone).
See also Tables S1 and S2.To further assess CRAFTT’s predictive ability, we performed
a global network analysis by computing the network path lengths
for all drug-TFpairs thatwere found tobe significant (FWER<0.1)
in the predictive GSEA step of our approach. As described
earlier, we reasoned that true drug-TF interactions should be
short, given the underlying mechanisms of the interactions (Fig-
ure 2A). Network analysis revealed that the network path lengths
(normalized shortest path) of our predicted specific drug-TFpairs
were significantly shorter than the path lengths of non-predic-
tions (FWER = 1.0) (p = 0.00313, Mann-Whitney test) (Figure 2B).
This is illustrated in Figure 2C, where we show a subnetwork
centered on HSF1 that includes drugs connected to HSF1 via
one or more intervening proteins. Predicted HSF1 inhibitors by
our transcriptomic approach are closer to HSF1 in this subnet-
work (red paths) compared to non-predicted molecules (yellow
paths). Altogether, this analysis indicates that our predictions
are not random and confirms that many drugs might disrupt
TFs by targeting regulatory or interacting cofactors. The network
analysis provided increased confidence in our approach’s pre-
dictive capacity. Moving forward, we used shorter drug-TF pathsCell Rto further prioritize drug-TF predictions
using our combined score (MI) (see
Experimental Procedures).
Identification and Validation of
Small Molecules that Inhibit the
TF ERG
We hypothesized that CRAFTT could be
used to identify molecules that inhibit
the activity of the pro-invasive, oncogenicTF ERG. This is of an interest due to ERG overexpression result-
ing from a tissue-specific gene fusion event that occurs in as
many as 50% of prostate cancer patients. This overexpression
results in a pro-invasive phenotype in prostate cancer (Elemento
et al., 2012; Rickman et al., 2010; Tomlins et al., 2008). We had
previously identified ERG target genes using ChIP-seq in
RWPE1 benign prostate cells (Rickman et al., 2012). We applied
our approach to all CMap drug profiles to identify candidate
drugs for inhibition of ERG.
From the prediction step of CRAFTT, we identified eight candi-
date drugs that downregulate ERG target genes: dexametha-
sone (FWER = 0.086), naproxen (FWER = 0.048), acemetacin
(FWER = 0.087), ondansetron (FWER = 0.061), epitiostanol
(FWER = 0.069), diloxanide (FWER = 0.003), methanthelinium
bromide (FWER = 0.046), and isoflupredone (FWER = 0.088).
Five of these candidate drugs were contained in our biological
network: dexamethasone (MI = 1,015.85), naproxen (MI =
530.90), acemetacin (MI = 2,167.88), ondansetron (MI = 3.35),
and epitiostanol (MI = 520.99) (Figure 3A). An initial network anal-
ysis suggested that dexamethasone, naproxen, acemetacin,eports 15, 2348–2356, June 14, 2016 2351
Dexamethasone
Drug NES PL MI MI*
Dexamethasone 2.13 3 1016 9.26
Naproxen 2.23 3 531 2.48
Acemetacin 2.16 3 2168 2.45
Ondansetron 2.26 4 3.35 2.42
Epitiostanol 2.19 3 521 0.90
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Figure 3. Identification of Dexamethasone
as a Candidate Drug for Inhibition of ERG
Activity
(A) Network visualization illustrating path lengths
from ERG to five candidate drugs for ERG inhibition
(dexamethasone, naproxen, acemetacin, ondan-
setron, and epitiostanol). The node sizes corre-
spond to the gene expression levels, with the larger
size representing a higher expression level. If low-
expression genes are removed (RPKM< 4), the path
lengths for naproxen and acemetacin are increased
while the paths from ondansetron and epitiostanol
are disrupted. The corresponding table shows
metrics that describe each of these drugs in relation
to ERG: NES is obtained from GSEA, PL is the
shortest network path length required to connect
ERG to the drug, and MI* is the MI after low-
expression genes were removed (RPKM < 4).
(B) Application of our method to dexamethasone
expression profiles and ERG target genes. The left
panel illustrates the results of theGSEA for ERG and
dexamethasone. The lowest plot of the left panel
shows the log2 differential expression profile for
dexamethasone, with the ERG target genesmarked
directly above. Above are the running enrichment
score and a histogram of the ERG target gene fre-
quency, which illustrates whether the gene set is
enriched in the under- or overexpression regions.
Themiddle panel shows a subnetwork that includes
all genes that were members of any shortest path
between ERG and dexamethasone. The right panel
illustrates our prediction that the application of
dexamethasone would result in the downregulation
of activity of ERG target genes.
(C) ERG target gene PLAU expression by RT-PCR in
cell lines expressing ERG (DU145-ERG and VCaP)
and controls (DU145-GFP) after treatment with
vehicle or dexamethasone.
(D) Cell invasion and migration in cell lines ex-
pressing ERG (DU145-ERG) and controls (DU145-
GFP). The data are shown at n = 4 representation
103 field of view.
(E) The binding of ERG and a control (immuno-
globulin G) by ChIP-PCR at the promoter of its
target gene PLAU and at a negative control
(ARHGEF) in cell lines expressing ERG (DU145-
ERG and VCaP).
Data are shown as mean ± SEM. Asterisks indicate
statistically significant differences by paired t test,
and n = 3 for each condition. *p < 0.05, **p < 0.01,
***p < 0.001; NS, not significant. See also Figure S2.and epitiostanol were the best candidates due to their large
modulation indices.
Next, we performed an additional analysis to use with our
CRAFTT methodology to further prioritize our drug candidate
list. We used gene expression (RNA sequencing) from RWPE1
prostate cells to filter out genes that have low expression in the
network, which we defined as reads per kb of transcript per
million mapped reads (RPKM) < 4. This analysis resulted in dexa-
methasone being identified as the drug with the shortest path
length and highest-modified MI (9.26) (Figure 3B).
Because dexamethasone has not been previously linked to
ERG, we next sought to experimentally test our hypothesis that2352 Cell Reports 15, 2348–2356, June 14, 2016dexamethasone would be able to reverse ERG-induced onco-
genic phenotypes through disruption of ERG in ERG-expressing
prostate cancer cells. One of the top target genes that was
reversed by dexamethasone in the CMap profile was the uroki-
nase plasminogen activator (PLAU), a known ERG target gene
that has been previously implicated in ERG-mediated cell inva-
sion in multiple cancers and models (Tomlins et al., 2008). We
found experimentally that dexamethasone abrogated expres-
sion of the ERG target gene PLAU in both DU145 cells express-
ing ERG and VCaP cells with high endogenous levels of ERG
(Figure 3C). In comparison, dexamethasone was weakly active
in the control GFP cells (Figure 3C).To further test the inhibitory
A B Figure 4. Extended Analyses of CRAFTT
Predictions
(A) Kaplan-Meier survival analysis for time from
first prescription of drug to prostate cancer diag-
nosis (censor point) using an age-adjusted cohort
of male patients was performed for patients
treated with dexamethasone, prednisone, simva-
statin, and the top-100 prescribed drugs. Statisti-
cal significance was assessed using a Cox
proportional hazards test for comparison of
dexamethasone to each other drug.
(B) The drug GI50 in mutant p53 and wild-type p53
cell lines in the National Cancer Institute (NCI) DTP.
Statistical significance was assessed using the
Mann-Whitney test.
See also Figures S3 and S4.effect of dexamethasone on ERG activity, we treated a ERG-
overexpressing cell line newly derived from PTEN//ERGRosa26
prostate tumors in transgenic mice (Chen et al., 2013). Consis-
tent with the commercially available human prostate cancer
cells, dexamethasone treatment resulted in a dose-dependent
decrease in mouse PLAU mRNA expression (Figure S2A).
Using cell invasion and migration assays, we then found that
dexamethasone significantly decreased cell invasion and migra-
tion in DU145 prostate cancer cells overexpressing ERG but not
in isogenic control cells (Figure 3D; Figure S2B). High-resolution
microscopic images revealed that dexamethasone helps the
cells partially regain polarity, which may be a potential mecha-
nism for reduced cell invasion (Figure S2C). As expected from
published literature on the mostly invasive oncogenic role of
ERG, we found that ERG inhibition via dexamethasone treatment
had no effect on cell viability in vitro (Figure S2D). Finally, we
found using ChIP-PCR that dexamethasone substantially
decreased binding of ERG at the PLAU promoter in both
DU145-ERGand VCaP cells (Figure 3E). Altogether, these exper-
imental results support CRAFTT’s computationally derived pre-
diction that dexamethasone inhibits ERG activity.
CRAFTT’s PredictedDexamethasone-ERG Interaction Is
Independent of AR and GR
Dexamethasone is a GR agonist, which suggests that GR, en-
coded by NR3C1, may play a role in ERG-mediated gene
expression. We found that small interfering RNAs targeting
NR3C1 mRNA lowered GR levels by 80% in the DU145-ERG
cells (Figure S2E). Although GR seems to play a role in PLAU
regulation in the absence of ERG, lowering GR levels did not
significantly alter dexamethasone’s impact on PLAU expression
in ERG-positive cells (Figure S2F). In addition, we found that AR
target genes were not substantially mobilized by dexametha-
sone, and screening of VCaP cells showed that dexamethasone
had little effect on AR signaling (Figure S2G). Altogether, these
results indicate that dexamethasone-mediated ERG inhibition
occurs independent of GR and AR signaling.
We next looked to see what CRAFTT would predict for predni-
sone, another glucocorticosteroid that is used in the treatment of
prostate cancer. We found that CRAFTT predicted prednisone
would not inhibit ERG activity, and subsequent experimentsinvolving prednisolone, the active form of prednisone, supported
this finding. Clinical trials for castration refractory prostate can-
cer (CRPC), in the absence of ERG fusion status, have suggested
that an advantage of using dexamethasone over prednisolone is
improved patient PSA response rates (37% on dexamethasone,
compared to 17% on prednisolone) (R. Venkitaraman et al.,
2013, Genitourin. Cancers Symp., conference).
Electronic Health Record Analyses Support CRAFTT’s
Predictions
To further investigate the correlation between dexamethasone
treatment and prostate cancer, we performed a retrospective
analysis of electronic health records (EHRs) at Columbia Univer-
sity Medical Center (CUMC). Kaplan-Meier survival analysis was
performed using the time from first prescription of drug to pros-
tate cancer diagnosis (censor point) on an age-adjusted cohort
of male patients (Figure S3). Significance was assessed using
the Cox proportional hazards test. Dexamethasone patients
had a statistically significant greater likelihood of not getting
diagnosed with prostate cancer than did patients on prednisone
(p < 0.001), patients on simvastatin (p < 0.001), and patients on
any of the top 100 prescribed drugs (p < 0.001) (Figure 4A). We
next constructed a logistic regression model to assess the rela-
tionship of the dexamethasone and other control treatments and
the prostate cancer diagnosis independent of known prostate
cancer confounders. The results of our regression model
showed a protective effect for dexamethasone administration
versus other control treatment groups that was independent of
other known risk factors. Thus, dexamethasone appears to be
both protective against prostate cancer (perhaps through its
inhibitory effect on ERG-rearranged tumors, as predicted in
this study) and more active than prednisolone in its protective
effect and in the treatment of CRPC. These results are still largely
correlative in the absence of ERGmolecular status for electronic
medical record (EMR) patients, whichwe could not obtain for this
study.
CRAFTT Predicts Candidate Drugs for Reactivating TF
Activity
CRAFTT also made predictions about drugs for transcriptional
reactivation. We found that there was an enrichment of histoneCell Reports 15, 2348–2356, June 14, 2016 2353
deacetylase inhibitors (p < 0.0001, permutation test) among our
reactivation predictions, indicating that CRAFTT is successful in
identifying true drug-TF interactions (Figure S4). Thus, we hy-
pothesized that we could identify a drug that reactivates the
tumor suppressor TF p53. The application of CRAFTT to p53
ChIP-seq (Kittler et al., 2013) and subsequent network analysis
identified promethazine (FWER < 0.001) as a therapeutic option
for reactivation of p53 activity. Analysis of Developmental Ther-
apeutics Program (DTP)-NCI60 drug sensitivity data (Reinhold
et al., 2012) supported this prediction, because we found that
the mutant p53 cell lines were significantly more sensitive to
promethazine than were the wild-type p53 cell lines (p =
0.0376, Mann-Whitney test) (Figure 4B). We next looked to see
whether any predicted drugs for p53 activity reactivation tar-
geted genes that had been previously identified as necessary
for growth in TP53-deficient cells (Xie et al., 2012). From that
list, we found seven of the drugs predicted by CRAFTT to reac-
tivate p53 activity target genes: pentetrazol, naftopidil, oxedrine,
capsaicin, ifenprodil, flumetasone, and dexpropranolol. Alto-
gether, this suggests that our approach can be used to identify
candidates for reactivation of TFs frequently lost in cancer.
DISCUSSION
Traditionally, TFs have been considered difficult to drug, and
attempts at identifying drugs that affect TFs have been unfruitful.
While breakthroughs have begun to experimentally identify mol-
ecules that indirectly modulate transcriptional activity, we pro-
pose a method (called CRAFTT) to do so computationally and
systematically. Because cancer subtypes are frequently associ-
ated with aberrant TF activity, often due to somatic mutations,
our approach has the potential to affect the development of
new therapeutic strategies in these subtypes.
We first looked to see whether CRAFTT could rediscover
known cases of drugs that affect TF activity. We found that
when we applied our method to transcriptional binding site
data and drug profiles from known cases, we could rediscover
these connections. We then used CRAFTT to identify dexameth-
asone as a candidate for inhibition of ERG activity; follow-up
experiments supported this prediction. We also found that
dexamethasone had a similar effect in isolated mouse cell lines
and in human cell lines. This suggests that mouse models could
be used for further follow-up on the therapeutic use of dexa-
methasone in treatment of the ERG-overexpression cancer
subtypes.
CRAFTT was successful in the identification of drugs for
affecting transcriptional activity, but some areas could further
improve its predictive capacities. While the shortest path anal-
ysis provides support for our predictions and is only used in
prediction prioritization, we cannot rule out that individual pre-
dictions may be affected by bad edges, especially in our pro-
tein-protein interaction network. However, a network sensitivity
analysis suggests that our network is robust to missing network
edges (see Supplemental Experimental Procedures). This is
likely due to the high interconnectivity of the network, which
has an average path length of 3.6. This high interconnectivity
also explains the bimodality in the normalized path lengths,
with the first and second peaks corresponding to shorter and2354 Cell Reports 15, 2348–2356, June 14, 2016longer observed path lengths, respectively, than average for a
drug-TF pair with the same network degree.
In addition, the ChIP-seq that we used to derive binding site
data was obtained from wild-type TFs. However, our approach
was able to capture true drug-TF interactions, at least partly
because these variants often cause constitutive expression
and binding of the TF instead of dramatic disruption and changes
to binding sites. As more mutant TF binding data become avail-
able, we will be able to adapt and apply our approach in a more
targeted and physiologically relevant manner. ChIP-seq peak
calling procedures are also known to be prone to error. While
we have taken steps to control for binding hotspots, our method
will benefit as improved peak calling methods become available.
Finally, the CMap data that we analyzed was in a collapsed
format, which limits the robustness of the predictions. The Broad
Institute has released an updated version of CMap, which in-
cludes a 1,000-fold scale-up and will better allow us to use the
variability in replicates. We also intend to apply CRAFTT to iden-
tification of candidate drugs for modulating the activity of other
TFs that are historically elusive but desirable for targeting, such
as FOXA1 and XBP1.
EXPERIMENTAL PROCEDURES
The CRAFTT Approach
CRAFTT requires two inputs for its predictions: ChIP-seq for a TF that is used
to derive its target gene set and drug-induced expression profiles. The
CRAFTT procedure (1) uses GSEA, with the target gene set for a TF and
drug-induced expression profiles as inputs, to make predictions about which
drugs modulate the TF’s activity and then (2) prioritizes predictions using
network analysis. For the network analysis, we compute a normalized path
length score (NPL), in which we calculate the probability of observing the
path length between the drug d and TF X (P(PLjd,X)) using 500 degree-preser-
ving randomized networks (Gobbi et al., 2014). These steps are combined to
generate a prediction score, the MI:
MId;X =
NESd;X
PðPL jd;XÞ
where
NPL=PðPL jd;XÞ=
X500
i =1
PLdxi ;Xxi < PLdg ;Xg
500
See the Supplemental Experimental Procedures for a more detailed descrip-
tion of the approach.
Statistical Analysis
The statistical significance for each of our predictions was estimated accord-
ing to the GSEA procedure (Subramanian et al., 2005). For the analysis of EMR,
Kaplan-Meier survival analysis was performed on an age-adjusted cohort, us-
ing time to first diagnosis of prostate cancer as the endpoint in our study and
excluding all patients with prior diagnosis of cancer. The Cox proportional haz-
ards test was used to assess significance. See the Supplemental Experimental
Procedures for a more detailed description of the EMR analysis. Statistical
analysis of RT-PCR, ChIP-PCR, cell invasion, and cell migration experiments
was done in Prism using paired t test and n = 3 for each condition.
All other statistically significance values were calculated in R. The permuta-
tion test (using 1,000 random permutations) was used to assess the signifi-
cance of the enrichment of TF alterations in COSMIC and the enrichment of
drug categories (e.g., HDAC inhibitors) within our predictions. The chi-square
test was used to compare the TF enrichment to that of kinases. The signifi-
cance for the enrichment of known interactions was calculated using the exact
binomial test, comparing the enrichment of known pairs to the total percentage
of drug-TF pairs that were predicted. The Mann-Whitney test was used to
assign significance to the network analysis and to the difference between
the concentration required to inhibit 50% of growth (GI50) values in wild-type
and the GI50 values in mutant p53 cell lines.
Experimental Validation
RWPE1, VCaP, and DU145 were obtained from ATCC andmaintained accord-
ing to the manufacturer’s protocol. Isogenic DU145 or RWPE1 ± ERG cell lines
were generated to overexpress truncated ERG, as previously described (Rick-
man et al., 2010, 2012). The PTEN//ERGRosa26 prostate cancer cells were
derived from PTEN//ERGRosa26 prostate tumors, as previously described
(Chen et al., 2013). The cells were treated with PBS and incubated with the
appropriate media at the indicated drug or vehicle dose for 24 or 48 hr. Cells
were then analyzed using ChIP-PCR, qRT-PCR, or invasion or migration
assay. ChIP-PCR, qRT-PCR, cell invasion assay, and migration assay were
performed as previously described (Rickman et al., 2010, 2012).
ChIP-PCR primers for all sites are listed in Table S3. Each sample was run in
triplicate. The amounts of target genes were calculated relative to the refer-
ence gene HMBS. See the Supplemental Experimental Procedures for more
details.
Supplemental Website
A supplemental website for CRAFTT has been made available at http://
physiology.med.cornell.edu/faculty/elemento/lab/data/CRAFTT/. This in-
cludes an expanded overview of the methodology, with examples and a tool
for querying predictions. We also have released our code on the website so
that users can test our approach on their own drug perturbation profiles
and/or TF target gene set of interest.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.05.037.
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